Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Date:2/24/2009

crease in revenue is primarily the result of lower product manufacturing revenues due to the termination of the company's inhaled insulin collaboration with Pfizer in late 2007.

Research and development expense was $154.4 million in 2008 as compared to $153.6 million for 2007. Included in the $154.4 million of overall research and development spending is approximately $82.0 million of new investments in Nektar preclinical and clinical development programs.

Nektar has also continued to make improvements to its operating efficiencies as compared to a year ago. For the twelve months ended December 31, 2008, the company's general and administrative expense was $51.5 million as compared to $57.3 million for the same period a year ago.

Net income for the quarter ended December 31, 2008 was $76.8 million or $0.83 per share, compared to net income of $39.0 million or $0.42 per share in the fourth quarter of 2007. For the year 2008, the company reported a net loss of $34.3 million or $0.37 per share, compared to a net loss of $32.8 million or $0.36 per share for 2007.

Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results

The company also announced that due to scheduling considerations, the conference call to review results will now be held on March 2, 2009 at 2 PM Pacific Time. Details are below:

Howard Robin, president and chief executive officer, and John Nicholson, chief financial officer, will host a conference call beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT) on Monday, March 2, 2009.

A live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com.

        To access the conference call, follow these instructions:
  
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
2. Nektar Announces Retirement of Irwin Lerner from Board of Directors
3. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Nektar Therapeutics to Webcast R&D Day on November 12th
6. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
10. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
11. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
(Date:7/24/2014)... 2014 Deep Research Report on Global ... and in-depth research report on Potassium Sulphate ... information, including its definition, classification, application, and industry ... the international market analysis, including China’s domestic market ... environment & economic situation analysis, the influence of ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
(Date:7/24/2014)... July 24, 2014  Spherix Incorporated (SPEX) -- an ... monetization of intellectual property, today announced that the Company ... June 30, 2014 on Monday, August 18, 2014 for ... a.m. ET on Monday, August 18, 2014 to discuss ... the company,s CEO, Anthony Hayes . ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Spherix Schedules Shareholder Update Call 2
... July 11 Signalife,Inc. (Amex: SGN ) ... proceed,with its previously-announced merger or similar business combination ... committee has been,appointed to proceed with due diligence ... As presently contemplated, a new parent,company will be ...
... July 11 Sigma-Aldrich Corporation,(Nasdaq: SIAL ), ... second,quarter results on Wednesday, July 23, 2008, at ... This call is being webcast by Thomson/CCBN and ... http://www.sigma-aldrich.com ., The webcast is also ...
... First-in-Man study success, Ovalum Ltd. launches a multicenter study using ... privately held Israeli medical device company, has announced today successful ... in the coronary arteries. , ... ...
Cached Biology Technology:Signalife Board Approves Merger 2Signalife Board Approves Merger 3Sigma-Aldrich Corporation's 2nd Quarter 2008 Earnings Conference Call 2Ovalum Ltd. Announces Success in Coronary Cases Using CiTop™ ExPander™ Guidewire 2
(Date:7/25/2014)... reach puberty is influenced by ,imprinted genes,a subset of genes ... This is the first evidence that imprinted genes can ... this study were published today in the journal Nature ... is a marker for the timing of puberty in females. ... between girls, is an inherited trait, and is linked to ...
(Date:7/25/2014)... Biometrics industry expands and becomes ... technology for online & commerce payments while seeking security ... GOOG ), LifeLock Inc. (NYSE: LOCK ... Inc. (NASDAQ: AAPL ) and Fortinet Inc. ... biometric authentication company focused on the growing m-commerce market, ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare ... cardiac devices, has cut emergency room wait times by ... Diego (UCSD) Medical Center, according to a recent study ... Emergency Departments are using the suite to access data ... or defibrillators. "Using Geneva,s technology platform we ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... often never reach the tumors they,re intended to ... because the blood vessels feeding the tumors are ... late Judah Folkman, MD, founder of the Vascular ... Biology researchers have discovered an explanation for these ...
... stunted growth and declining fertility among small crustaceans in ... new research shows. The finding adds to mounting ... are a deadly diet for many sea creatures. ... of the Total Environment , reveal genetic mutations among ...
... us, many wonder if the roof over their heads will ... week, inaugural tests at The University of Western Ontario,s ,Three ... Homes will begin to provide answers as researchers ,raze the ... the first of its kind in the world to subject ...
Cached Biology News:Normalizing tumor vessels to improve cancer therapy 2Normalizing tumor vessels to improve cancer therapy 3Heavy metal link to mutations, low growth and fertility among crustaceans in Sydney Harbor tributary 2
... GCpro Taq DNA Polymerase is a ... advantages for all PCR applications. GCpro Taq ... clone expressed in E. coli, containing the ... The enzyme includes a highly processive 5'-3' ...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
Biology Products: